What's in Daewoong Pharmaceutical Co. LTD.'s pipeline?

Daewoong Pharmaceutical Co. LTD. has 134 drugs in our index: 14 marketed, 0 filed, 36 in Phase 3, 6 in Phase 2, 78 in Phase 1.

Which companies overlap with Daewoong Pharmaceutical Co. LTD.'s portfolio?

Top competitors by shared drug class: AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme LLC, Sanofi, Hanmi Pharmaceutical Company Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/daewoong-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Daewoong Pharmaceutical Co. LTD. — Portfolio Competitive Intelligence Brief

Daewoong Pharmaceutical Co. LTD. pipeline: 14 marketed, 0 filed, 36 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

14 marketed 0 filed 36 Phase 3 6 Phase 2 78 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
URSO Forte	URSO Forte	marketed
Fexuprazan Hydrochloride	Fexuprazan Hydrochloride	marketed	Potassium-competitive acid blocker (P-CAB)	H+/K+-ATPase (proton pump)	Gastroenterology
Tiropramide HCl 100mg	Tiropramide HCl 100mg	marketed
Clostridium Botulinum A Toxin	Clostridium Botulinum A Toxin	marketed
Placebo of DWJ1464	Placebo of DWJ1464	marketed
Axid Capsule 150mg	Axid Capsule 150mg	marketed
Ursodeoxycholic acid, thiamine, riboflavin	Ursodeoxycholic acid, thiamine, riboflavin	marketed
Mucotra SR Tablet 150mg	Mucotra SR Tablet 150mg	marketed
Albis Tab	Albis Tab	marketed
Vemliver tablet	Vemliver tablet	marketed
DWJ1464	DWJ1464	marketed			Other
Single group, open-label	Single group, open-label	marketed

Therapeutic area mix

Diabetes · 8
Neurology · 6
Other · 5
Oncology · 3
Endocrinology / Diabetes · 3
Gastroenterology · 2
Cardiovascular · 2
Pain management · 1
Gastrointestinal · 1
Gastrointestinal / Digestive Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 7 shared drug classes
GlaxoSmithKline · 6 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
Sanofi · 6 shared drug classes
Hanmi Pharmaceutical Company Limited · 5 shared drug classes
Ain Shams University · 4 shared drug classes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 4 shared drug classes
AbbVie · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Daewoong Pharmaceutical Co. LTD.:

Cite this brief

Drug Landscape (2026). Daewoong Pharmaceutical Co. LTD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/daewoong-pharmaceutical-co-ltd. Accessed 2026-05-16.